New drug combo takes on advanced cancers in early trial

NCT ID NCT07123415

Recruiting now Disease control Sponsor: Aptabio Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This early-phase study tests a new drug called APX-343A, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shows any signs of shrinking tumors. About 110 adults with advanced cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Gangnam Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea

Contact
Seoul National University Bundang Hospital
RECRUITING

Seongnam, South Korea

Contact
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID CANCER ADVANCED SOLID TUMOR (PHASE 1)